Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02407912|
Recruitment Status : Recruiting
First Posted : April 3, 2015
Last Update Posted : November 20, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pleural Effusion, Malignant||Drug: cisplatin||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer.|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||March 2018|
|Estimated Study Completion Date :||March 2020|
75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
ciplatin in distilled water is injected into the chest for 48 h.
Other Name: cisplatinum
No Intervention: Control
No intervention was applied.
- overall response rate [ Time Frame: one month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02407912
|Contact: Hongbiao Wang, Masteremail@example.com|
|Department of medical oncology||Recruiting|
|Shantou, Guangdong, China, 515031|
|Contact: Hongbiao Wang, Master 8613592882093 firstname.lastname@example.org|
|Principal Investigator:||Hongbiao Wang, Master||Cancer Hospital of Shantou University|